Vol. 45 (2): 215-219, March – April, 2019
doi: 10.1590/S1677-5538.IBJU.2019.02.03
DIFFERENCE OF OPINION
Saum Ghodoussipour 1, Amir Lebastchi 2, Peter Pinto 2, Andre Berger 1
1 Department of Urology, University of Southern California, Los Angeles, California, USA; 2 National Cancer Institute – NCI, Bethesda, Maryland, USA
Keywords: Prostatic Neoplasms; Risk Reduction Behavior; Watchful Waiting; Therapeutics
Prostate cancer (PC) is diagnosed in over 170,000 men in the United States each year. While this makes PC one of the most common solid malignancies in men, a significant majority will not die from PC but from other unrelated causes (1). In fact, almost half of men with screening detected and localized PC are considered candidates for deferred treatment (2). In an effort to decrease the morbidity associated with overtreatment, guideline panels now recommend active surveillance (AS) for those with low risk (LR) disease (3-5).
